Nanovibronix (NASDAQ:FEED – Get Free Report) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its peers? We will compare Nanovibronix to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Profitability
This table compares Nanovibronix and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Nanovibronix Competitors | -672.41% | -133.75% | -59.01% |
Earnings & Valuation
This table compares Nanovibronix and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | -$3.70 million | -0.06 |
| Nanovibronix Competitors | $59.54 million | -$32.15 million | 4.35 |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Nanovibronix and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Nanovibronix Competitors | 77 | 77 | 158 | 6 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 41.87%. Given Nanovibronix’s peers stronger consensus rating and higher possible upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its peers.
Insider & Institutional Ownership
16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 1.4% of Nanovibronix shares are owned by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Nanovibronix has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s peers have a beta of 1.76, indicating that their average share price is 76% more volatile than the S&P 500.
Summary
Nanovibronix peers beat Nanovibronix on 8 of the 13 factors compared.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
